0
USD
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Urological Cancer Therapeutics Drugs Market Research Report 2020
Published Date: March 2020
|
Report Code: QYRE-Auto-29K1809
Home | Category |Health |Men s Health
Global Urological Cancer Therapeutics Drugs Market Research Report 2020

Global Urological Cancer Therapeutics Drugs Market Research Report 2020

Code: QYRE-Auto-29K1809
Report
March 2020
120 Pages
QYResearch
Region: Global, North America, China, Europe, France, Germany,
Description
Table of Content
Tables & Figures
The global Urological Cancer Therapeutics Drugs market is valued at US$ xx million in 2020 is expected to reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2021-2026.
This report focuses on Urological Cancer Therapeutics Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Urological Cancer Therapeutics Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.
Market Segment Analysis
The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type, the Urological Cancer Therapeutics Drugs market is segmented into
    Xofigo (radium Ra 223 dichloride)
    Jevtana (cabazitaxel)
    Inlyta (axitinib)
    Votrient (pazopanib hydrochloride)
    Sutent (sunitinib malate)
    Zytiga (abiraterone acetate)
    Xtandi (enzalutamide)
    Opdivo (nivolumab)
    Provenge (sipuleucel-T)
Segment by Application
    Hospital
    Medical Research Laboratory
    Others
 Global Urological Cancer Therapeutics Drugs Market: Regional Analysis
The Urological Cancer Therapeutics Drugs market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the Urological Cancer Therapeutics Drugs market report are:
North America
    U.S.
    Canada
Europe
    Germany
    France
    U.K.
    Italy
    Russia
Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
Latin America
    Mexico
    Brazil
    Argentina
Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E
Global Urological Cancer Therapeutics Drugs Market: Competitive Analysis
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
The major players in global Urological Cancer Therapeutics Drugs market include:
    Novartis
    Pfizer
    Johnson & Johnson
    AstraZeneca
    Astellas
    Bristol-Myers Squibb
    Abbott Laboratories
    Celgene Corporation
    Dendreon Corporation
    Ferring Pharmaceuticals
    GlaxoSmithKline plc
    Indevus Pharmaceuticals Inc
    Ipsen
    Roche Healthcare
    Sanofi S.A.
Table of Contents
1 Urological Cancer Therapeutics Drugs Market Overview
1.1 Product Overview and Scope of Urological Cancer Therapeutics Drugs
1.2 Urological Cancer Therapeutics Drugs Segment by Type
1.2.1 Global Urological Cancer Therapeutics Drugs Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 Xofigo (radium Ra 223 dichloride)
1.2.3 Jevtana (cabazitaxel)
1.2.4 Inlyta (axitinib)
1.2.5 Votrient (pazopanib hydrochloride)
1.2.6 Sutent (sunitinib malate)
1.2.7 Zytiga (abiraterone acetate)
1.2.8 Xtandi (enzalutamide)
1.2.9 Opdivo (nivolumab)
1.2.10 Provenge (sipuleucel-T)
1.3 Urological Cancer Therapeutics Drugs Segment by Application
1.3.1 Urological Cancer Therapeutics Drugs Sales Comparison by Application: 2020 VS 2026
1.3.2 Hospital
1.3.3 Medical Research Laboratory
1.3.4 Others
1.4 Global Urological Cancer Therapeutics Drugs Market Size Estimates and Forecasts
1.4.1 Global Urological Cancer Therapeutics Drugs Revenue 2015-2026
1.4.2 Global Urological Cancer Therapeutics Drugs Sales 2015-2026
1.4.3 Urological Cancer Therapeutics Drugs Market Size by Region: 2020 Versus 2026
2 Global Urological Cancer Therapeutics Drugs Market Competition by Manufacturers
2.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Manufacturers (2015-2020)
2.2 Global Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2015-2020)
2.3 Global Urological Cancer Therapeutics Drugs Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Urological Cancer Therapeutics Drugs Manufacturing Sites, Area Served, Product Type
2.5 Urological Cancer Therapeutics Drugs Market Competitive Situation and Trends
2.5.1 Urological Cancer Therapeutics Drugs Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Urological Cancer Therapeutics Drugs Players (Opinion Leaders)
3 Urological Cancer Therapeutics Drugs Retrospective Market Scenario by Region
3.1 Global Urological Cancer Therapeutics Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Urological Cancer Therapeutics Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
3.3.1 North America Urological Cancer Therapeutics Drugs Sales by Country
3.3.2 North America Urological Cancer Therapeutics Drugs Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
3.4.1 Europe Urological Cancer Therapeutics Drugs Sales by Country
3.4.2 Europe Urological Cancer Therapeutics Drugs Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Urological Cancer Therapeutics Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region
3.5.2 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
3.6.1 Latin America Urological Cancer Therapeutics Drugs Sales by Country
3.6.2 Latin America Urological Cancer Therapeutics Drugs Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country
3.7.2 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Urological Cancer Therapeutics Drugs Historic Market Analysis by Type
4.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
4.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2015-2020)
4.3 Global Urological Cancer Therapeutics Drugs Price Market Share by Type (2015-2020)
4.4 Global Urological Cancer Therapeutics Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Global Urological Cancer Therapeutics Drugs Historic Market Analysis by Application
5.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
5.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2015-2020)
5.3 Global Urological Cancer Therapeutics Drugs Price by Application (2015-2020)
6 Company Profiles and Key Figures in Urological Cancer Therapeutics Drugs Business
6.1 Novartis
6.1.1 Corporation Information
6.1.2 Novartis Description, Business Overview and Total Revenue
6.1.3 Novartis Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Novartis Products Offered
6.1.5 Novartis Recent Development
6.2 Pfizer
6.2.1 Pfizer Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.2.2 Pfizer Description, Business Overview and Total Revenue
6.2.3 Pfizer Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Pfizer Products Offered
6.2.5 Pfizer Recent Development
6.3 Johnson & Johnson
6.3.1 Johnson & Johnson Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.3.2 Johnson & Johnson Description, Business Overview and Total Revenue
6.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Johnson & Johnson Products Offered
6.3.5 Johnson & Johnson Recent Development
6.4 AstraZeneca
6.4.1 AstraZeneca Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.4.2 AstraZeneca Description, Business Overview and Total Revenue
6.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.4.4 AstraZeneca Products Offered
6.4.5 AstraZeneca Recent Development
6.5 Astellas
6.5.1 Astellas Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.5.2 Astellas Description, Business Overview and Total Revenue
6.5.3 Astellas Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Astellas Products Offered
6.5.5 Astellas Recent Development
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.6.2 Bristol-Myers Squibb Description, Business Overview and Total Revenue
6.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.6.4 Bristol-Myers Squibb Products Offered
6.6.5 Bristol-Myers Squibb Recent Development
6.7 Abbott Laboratories
6.6.1 Abbott Laboratories Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.6.2 Abbott Laboratories Description, Business Overview and Total Revenue
6.6.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Abbott Laboratories Products Offered
6.7.5 Abbott Laboratories Recent Development
6.8 Celgene Corporation
6.8.1 Celgene Corporation Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.8.2 Celgene Corporation Description, Business Overview and Total Revenue
6.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.8.4 Celgene Corporation Products Offered
6.8.5 Celgene Corporation Recent Development
6.9 Dendreon Corporation
6.9.1 Dendreon Corporation Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.9.2 Dendreon Corporation Description, Business Overview and Total Revenue
6.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Dendreon Corporation Products Offered
6.9.5 Dendreon Corporation Recent Development
6.10 Ferring Pharmaceuticals
6.10.1 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.10.2 Ferring Pharmaceuticals Description, Business Overview and Total Revenue
6.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.10.4 Ferring Pharmaceuticals Products Offered
6.10.5 Ferring Pharmaceuticals Recent Development
6.11 GlaxoSmithKline plc
6.11.1 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.11.2 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Description, Business Overview and Total Revenue
6.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.11.4 GlaxoSmithKline plc Products Offered
6.11.5 GlaxoSmithKline plc Recent Development
6.12 Indevus Pharmaceuticals Inc
6.12.1 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.12.2 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Description, Business Overview and Total Revenue
6.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.12.4 Indevus Pharmaceuticals Inc Products Offered
6.12.5 Indevus Pharmaceuticals Inc Recent Development
6.13 Ipsen
6.13.1 Ipsen Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.13.2 Ipsen Urological Cancer Therapeutics Drugs Description, Business Overview and Total Revenue
6.13.3 Ipsen Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.13.4 Ipsen Products Offered
6.13.5 Ipsen Recent Development
6.14 Roche Healthcare
6.14.1 Roche Healthcare Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.14.2 Roche Healthcare Urological Cancer Therapeutics Drugs Description, Business Overview and Total Revenue
6.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.14.4 Roche Healthcare Products Offered
6.14.5 Roche Healthcare Recent Development
6.15 Sanofi S.A.
6.15.1 Sanofi S.A. Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.15.2 Sanofi S.A. Urological Cancer Therapeutics Drugs Description, Business Overview and Total Revenue
6.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.15.4 Sanofi S.A. Products Offered
6.15.5 Sanofi S.A. Recent Development
7 Urological Cancer Therapeutics Drugs Manufacturing Cost Analysis
7.1 Urological Cancer Therapeutics Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs
7.4 Urological Cancer Therapeutics Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Urological Cancer Therapeutics Drugs Distributors List
8.3 Urological Cancer Therapeutics Drugs Customers
9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis
10 Global Market Forecast
10.1 Global Urological Cancer Therapeutics Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Urological Cancer Therapeutics Drugs by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Urological Cancer Therapeutics Drugs by Type (2021-2026)
10.2 Urological Cancer Therapeutics Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Urological Cancer Therapeutics Drugs by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Urological Cancer Therapeutics Drugs by Application (2021-2026)
10.3 Urological Cancer Therapeutics Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Urological Cancer Therapeutics Drugs by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Urological Cancer Therapeutics Drugs by Region (2021-2026)
10.4 North America Urological Cancer Therapeutics Drugs Estimates and Projections (2021-2026)
10.5 Europe Urological Cancer Therapeutics Drugs Estimates and Projections (2021-2026)
10.6 Asia Pacific Urological Cancer Therapeutics Drugs Estimates and Projections (2021-2026)
10.7 Latin America Urological Cancer Therapeutics Drugs Estimates and Projections (2021-2026)
10.8 Middle East and Africa Urological Cancer Therapeutics Drugs Estimates and Projections (2021-2026)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
    Table 1. Global Urological Cancer Therapeutics Drugs Sales (K MT) Growth Rate Comparison by Type (2015-2026)
    Table 2. Global Urological Cancer Therapeutics Drugs Sales (K MT) Comparison by Application: 2020 VS 2026
    Table 3. Global Urological Cancer Therapeutics Drugs Market Size by Type (K MT) (US$ Million) (2020 VS 2026)
    Table 4. Global Key Urological Cancer Therapeutics Drugs Manufacturers Covered in This Study
    Table 5. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Manufacturers (2015-2020)
    Table 6. Global Urological Cancer Therapeutics Drugs Sales Share by Manufacturers (2015-2020)
    Table 7. Global Urological Cancer Therapeutics Drugs Revenue (Million USD) by Manufacturers (2015-2020)
    Table 8. Global Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2015-2020)
    Table 9. Global Market Urological Cancer Therapeutics Drugs Average Price (USD/MT) of Key Manufacturers (2015-2020)
    Table 10. Manufacturers Urological Cancer Therapeutics Drugs Sales Sites and Area Served
    Table 11. Manufacturers Urological Cancer Therapeutics Drugs Product Types
    Table 12. Global Urological Cancer Therapeutics Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Urological Cancer Therapeutics Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2019)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Main Points Interviewed from Key Urological Cancer Therapeutics Drugs Players
    Table 16. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Region (2015-2020)
    Table 17. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region (2015-2020)
    Table 18. Global Urological Cancer Therapeutics Drugs Revenue (Million US$) by Region (2015-2020)
    Table 19. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2015-2020)
    Table 20. North America Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)
    Table 21. North America Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)
    Table 22. North America Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 23. North America Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)
    Table 24. Europe Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)
    Table 25. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)
    Table 26. Europe Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 27. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)
    Table 28. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region (2015-2020) (K MT)
    Table 29. Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Region (2015-2020)
    Table 30. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region (2015-2020) (US$ Million)
    Table 31. Asia Pacific Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2015-2020)
    Table 32. Latin America Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)
    Table 33. Latin America Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)
    Table 34. Latin America Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 35. Latin America Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)
    Table 36. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)
    Table 37. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)
    Table 38. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 39. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)
    Table 40. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2015-2020)
    Table 41. Global Urological Cancer Therapeutics Drugs Sales Share by Type (2015-2020)
    Table 42. Global Urological Cancer Therapeutics Drugs Revenue (Million US$) by Type (2015-2020)
    Table 43. Global Urological Cancer Therapeutics Drugs Revenue Share by Type (2015-2020)
    Table 44. Global Urological Cancer Therapeutics Drugs Price (USD/MT) by Type (2015-2020)
    Table 45. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Application (2015-2020)
    Table 46. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
    Table 47. Global Urological Cancer Therapeutics Drugs Sales Growth Rate by Application (2015-2020)
    Table 48. Novartis Urological Cancer Therapeutics Drugs Corporation Information
    Table 49. Novartis Description and Business Overview
    Table 50. Novartis Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 51. Novartis Main Product
    Table 52. Novartis Recent Development
    Table 53. Pfizer Urological Cancer Therapeutics Drugs Corporation Information
    Table 54. Pfizer Corporation Information
    Table 55. Pfizer Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 56. Pfizer Main Product
    Table 57. Pfizer Recent Development
    Table 58. Johnson & Johnson Urological Cancer Therapeutics Drugs Corporation Information
    Table 59. Johnson & Johnson Corporation Information
    Table 60. Johnson & Johnson Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 61. Johnson & Johnson Main Product
    Table 62. Johnson & Johnson Recent Development
    Table 63. AstraZeneca Urological Cancer Therapeutics Drugs Corporation Information
    Table 64. AstraZeneca Corporation Information
    Table 65. AstraZeneca Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 66. AstraZeneca Main Product
    Table 67. AstraZeneca Recent Development
    Table 68. Astellas Urological Cancer Therapeutics Drugs Corporation Information
    Table 69. Astellas Corporation Information
    Table 70. Astellas Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 71. Astellas Main Product
    Table 72. Astellas Recent Development
    Table 73. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Corporation Information
    Table 74. Bristol-Myers Squibb Corporation Information
    Table 75. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 76. Bristol-Myers Squibb Main Product
    Table 77. Bristol-Myers Squibb Recent Development
    Table 78. Abbott Laboratories Urological Cancer Therapeutics Drugs Corporation Information
    Table 79. Abbott Laboratories Corporation Information
    Table 80. Abbott Laboratories Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 81. Abbott Laboratories Main Product
    Table 82. Abbott Laboratories Recent Development
    Table 83. Celgene Corporation Urological Cancer Therapeutics Drugs Corporation Information
    Table 84. Celgene Corporation Corporation Information
    Table 85. Celgene Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 86. Celgene Corporation Main Product
    Table 87. Celgene Corporation Recent Development
    Table 88. Dendreon Corporation Urological Cancer Therapeutics Drugs Corporation Information
    Table 89. Dendreon Corporation Corporation Information
    Table 90. Dendreon Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 91. Dendreon Corporation Main Product
    Table 92. Dendreon Corporation Recent Development
    Table 93. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Corporation Information
    Table 94. Ferring Pharmaceuticals Corporation Information
    Table 95. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 96. Ferring Pharmaceuticals Main Product
    Table 97. Ferring Pharmaceuticals Recent Development
    Table 98. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Corporation Information
    Table 99. GlaxoSmithKline plc Corporation Information
    Table 100. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 101. GlaxoSmithKline plc Main Product
    Table 102. GlaxoSmithKline plc Recent Development
    Table 103. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Corporation Information
    Table 104. Indevus Pharmaceuticals Inc Corporation Information
    Table 105. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 106. Indevus Pharmaceuticals Inc Main Product
    Table 107. Indevus Pharmaceuticals Inc Recent Development
    Table 108. Ipsen Urological Cancer Therapeutics Drugs Corporation Information
    Table 109. Ipsen Corporation Information
    Table 110. Ipsen Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 111. Ipsen Main Product
    Table 112. Ipsen Recent Development
    Table 113. Roche Healthcare Urological Cancer Therapeutics Drugs Corporation Information
    Table 114. Roche Healthcare Corporation Information
    Table 115. Roche Healthcare Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 116. Roche Healthcare Main Product
    Table 117. Roche Healthcare Recent Development
    Table 118. Sanofi S.A. Urological Cancer Therapeutics Drugs Corporation Information
    Table 119. Sanofi S.A. Corporation Information
    Table 120. Sanofi S.A. Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 121. Sanofi S.A. Main Product
    Table 122. Sanofi S.A. Recent Development
    Table 123. Sales Base and Market Concentration Rate of Raw Material
    Table 124. Key Suppliers of Raw Materials
    Table 125. Urological Cancer Therapeutics Drugs Distributors List
    Table 126. Urological Cancer Therapeutics Drugs Customers List
    Table 127. Market Key Trends
    Table 128. Key Opportunities and Drivers: Impact Analysis (2021-2026)
    Table 129. Key Challenges
    Table 130. Global Urological Cancer Therapeutics Drugs Sales (K MT) Forecast by Type (2021-2026)
    Table 131. Global Urological Cancer Therapeutics Drugs Sales Market Share Forecast by Type (2021-2026)
    Table 132. Global Urological Cancer Therapeutics Drugs Revenue (Million US$) Forecast by Type (2021-2026)
    Table 133. Global Urological Cancer Therapeutics Drugs Revenue (Million US$) Market Share Forecast by Type (2021-2026)
    Table 134. Global Urological Cancer Therapeutics Drugs Sales (K MT) Forecast by Application (2021-2026)
    Table 135. Global Urological Cancer Therapeutics Drugs Revenue (Million US$) Forecast by Application (2021-2026)
    Table 136. Global Urological Cancer Therapeutics Drugs Sales (K MT) Forecast by Region (2021-2026)
    Table 137. Global Urological Cancer Therapeutics Drugs Sales Market Share Forecast by Region (2021-2026)
    Table 138. Global Urological Cancer Therapeutics Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
    Table 139. Global Urological Cancer Therapeutics Drugs Revenue Market Share Forecast by Region (2021-2026)
    Table 140. Research Programs/Design for This Report
    Table 141. Key Data Information from Secondary Sources
    Table 142. Key Data Information from Primary Sources
List of Figures
    Figure 1. Picture of Urological Cancer Therapeutics Drugs
    Figure 2. Global Urological Cancer Therapeutics Drugs Sales Market Share by Type: 2020 VS 2026
    Figure 3. Xofigo (radium Ra 223 dichloride) Product Picture
    Figure 4. Jevtana (cabazitaxel) Product Picture
    Figure 5. Inlyta (axitinib) Product Picture
    Figure 6. Votrient (pazopanib hydrochloride) Product Picture
    Figure 7. Sutent (sunitinib malate) Product Picture
    Figure 8. Zytiga (abiraterone acetate) Product Picture
    Figure 9. Xtandi (enzalutamide) Product Picture
    Figure 10. Opdivo (nivolumab) Product Picture
    Figure 11. Provenge (sipuleucel-T) Product Picture
    Figure 12. Global Urological Cancer Therapeutics Drugs Consumption Market Share by Application: 2020 VS 2026
    Figure 13. Hospital
    Figure 14. Medical Research Laboratory
    Figure 15. Others
    Figure 16. Global Urological Cancer Therapeutics Drugs Market Size 2015-2026 (US$ Million)
    Figure 17. Global Urological Cancer Therapeutics Drugs Sales Capacity (K MT) (2015-2026)
    Figure 18. Global Urological Cancer Therapeutics Drugs Market Size Market Share by Region: 2020 Versus 2026
    Figure 19. Urological Cancer Therapeutics Drugs Sales Share by Manufacturers in 2020
    Figure 20. Global Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers in 2019
    Figure 21. The Global 5 and 10 Largest Players: Market Share by Urological Cancer Therapeutics Drugs Revenue in 2019
    Figure 22. Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
    Figure 23. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region (2015-2020)
    Figure 24. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region in 2019
    Figure 25. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2015-2020)
    Figure 26. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region in 2019
    Figure 27. North America Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019
    Figure 28. North America Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019
    Figure 29. U.S. Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 30. U.S. Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 31. Canada Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 32. Canada Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 33. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019
    Figure 34. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019
    Figure 35. Germany Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 36. Germany Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 37. France Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 38. France Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 39. U.K. Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 40. U.K. Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 41. Italy Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 42. Italy Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 43. Russia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 44. Russia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 45. Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Region in 2019
    Figure 46. Asia Pacific Urological Cancer Therapeutics Drugs Revenue Market Share by Region in 2019
    Figure 47. China Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 48. China Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 49. Japan Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 50. Japan Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 51. South Korea Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 52. South Korea Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 53. India Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 54. India Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 55. Australia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 56. Australia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 57. Taiwan Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 58. Taiwan Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 59. Indonesia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 60. Indonesia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 61. Thailand Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 62. Thailand Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 63. Malaysia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 64. Malaysia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 65. Philippines Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 66. Philippines Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 67. Vietnam Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 68. Vietnam Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 69. Latin America Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019
    Figure 70. Latin America Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019
    Figure 71. Mexico Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 72. Mexico Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 73. Brazil Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 74. Brazil Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 75. Argentina Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 76. Argentina Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 77. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019
    Figure 78. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019
    Figure 79. Turkey Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 80. Turkey Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 81. Saudi Arabia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 82. Saudi Arabia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 83. U.A.E Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 84. U.A.E Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 85. Sales Market Share of Urological Cancer Therapeutics Drugs by Type (2015-2020)
    Figure 86. Sales Market Share of Urological Cancer Therapeutics Drugs by Type in 2019
    Figure 87. Revenue Share of Urological Cancer Therapeutics Drugs by Type (2015-2020)
    Figure 88. Revenue Market Share of Urological Cancer Therapeutics Drugs by Type in 2019
    Figure 89. Global Urological Cancer Therapeutics Drugs Sales Growth by Type (2015-2020) (K MT)
    Figure 90. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
    Figure 91. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application in 2019
    Figure 92. Global Revenue Share of Urological Cancer Therapeutics Drugs by Application (2015-2020)
    Figure 93. Global Revenue Share of Urological Cancer Therapeutics Drugs by Application in 2020
    Figure 94. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 95. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 96. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 97. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 98. Astellas Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 99. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 100. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 101. Celgene Corporation Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 102. Dendreon Corporation Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 103. Ferring Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 104. GlaxoSmithKline plc Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 105. Indevus Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 106. Ipsen Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 107. Roche Healthcare Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 108. Sanofi S.A. Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 109. Price Trend of Key Raw Materials
    Figure 110. Manufacturing Cost Structure of Urological Cancer Therapeutics Drugs
    Figure 111. Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs
    Figure 112. Urological Cancer Therapeutics Drugs Industrial Chain Analysis
    Figure 113. Channels of Distribution
    Figure 114. Distributors Profiles
    Figure 115. Porter's Five Forces Analysis
    Figure 116. North America Urological Cancer Therapeutics Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 117. North America Urological Cancer Therapeutics Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 118. Europe Urological Cancer Therapeutics Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 119. Europe Urological Cancer Therapeutics Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 120. Latin America Urological Cancer Therapeutics Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 121. Latin America Urological Cancer Therapeutics Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 122. Middle East and Africa Urological Cancer Therapeutics Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 123. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 124. Asia Pacific Urological Cancer Therapeutics Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 125. Asia Pacific Urological Cancer Therapeutics Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 126. Bottom-up and Top-down Approaches for This Report
    Figure 127. Data Triangulation
    Figure 128. Key Executives Interviewed
The global Urological Cancer Therapeutics Drugs market is valued at US$ xx million in 2020 is expected to reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2021-2026.
This report focuses on Urological Cancer Therapeutics Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Urological Cancer Therapeutics Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.
Market Segment Analysis
The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type, the Urological Cancer Therapeutics Drugs market is segmented into
    Xofigo (radium Ra 223 dichloride)
    Jevtana (cabazitaxel)
    Inlyta (axitinib)
    Votrient (pazopanib hydrochloride)
    Sutent (sunitinib malate)
    Zytiga (abiraterone acetate)
    Xtandi (enzalutamide)
    Opdivo (nivolumab)
    Provenge (sipuleucel-T)
Segment by Application
    Hospital
    Medical Research Laboratory
    Others
 Global Urological Cancer Therapeutics Drugs Market: Regional Analysis
The Urological Cancer Therapeutics Drugs market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the Urological Cancer Therapeutics Drugs market report are:
North America
    U.S.
    Canada
Europe
    Germany
    France
    U.K.
    Italy
    Russia
Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
Latin America
    Mexico
    Brazil
    Argentina
Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E
Global Urological Cancer Therapeutics Drugs Market: Competitive Analysis
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
The major players in global Urological Cancer Therapeutics Drugs market include:
    Novartis
    Pfizer
    Johnson & Johnson
    AstraZeneca
    Astellas
    Bristol-Myers Squibb
    Abbott Laboratories
    Celgene Corporation
    Dendreon Corporation
    Ferring Pharmaceuticals
    GlaxoSmithKline plc
    Indevus Pharmaceuticals Inc
    Ipsen
    Roche Healthcare
    Sanofi S.A.
Read More
Table of Contents
1 Urological Cancer Therapeutics Drugs Market Overview
1.1 Product Overview and Scope of Urological Cancer Therapeutics Drugs
1.2 Urological Cancer Therapeutics Drugs Segment by Type
1.2.1 Global Urological Cancer Therapeutics Drugs Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 Xofigo (radium Ra 223 dichloride)
1.2.3 Jevtana (cabazitaxel)
1.2.4 Inlyta (axitinib)
1.2.5 Votrient (pazopanib hydrochloride)
1.2.6 Sutent (sunitinib malate)
1.2.7 Zytiga (abiraterone acetate)
1.2.8 Xtandi (enzalutamide)
1.2.9 Opdivo (nivolumab)
1.2.10 Provenge (sipuleucel-T)
1.3 Urological Cancer Therapeutics Drugs Segment by Application
1.3.1 Urological Cancer Therapeutics Drugs Sales Comparison by Application: 2020 VS 2026
1.3.2 Hospital
1.3.3 Medical Research Laboratory
1.3.4 Others
1.4 Global Urological Cancer Therapeutics Drugs Market Size Estimates and Forecasts
1.4.1 Global Urological Cancer Therapeutics Drugs Revenue 2015-2026
1.4.2 Global Urological Cancer Therapeutics Drugs Sales 2015-2026
1.4.3 Urological Cancer Therapeutics Drugs Market Size by Region: 2020 Versus 2026
2 Global Urological Cancer Therapeutics Drugs Market Competition by Manufacturers
2.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Manufacturers (2015-2020)
2.2 Global Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2015-2020)
2.3 Global Urological Cancer Therapeutics Drugs Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Urological Cancer Therapeutics Drugs Manufacturing Sites, Area Served, Product Type
2.5 Urological Cancer Therapeutics Drugs Market Competitive Situation and Trends
2.5.1 Urological Cancer Therapeutics Drugs Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Urological Cancer Therapeutics Drugs Players (Opinion Leaders)
3 Urological Cancer Therapeutics Drugs Retrospective Market Scenario by Region
3.1 Global Urological Cancer Therapeutics Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Urological Cancer Therapeutics Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
3.3.1 North America Urological Cancer Therapeutics Drugs Sales by Country
3.3.2 North America Urological Cancer Therapeutics Drugs Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
3.4.1 Europe Urological Cancer Therapeutics Drugs Sales by Country
3.4.2 Europe Urological Cancer Therapeutics Drugs Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Urological Cancer Therapeutics Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region
3.5.2 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
3.6.1 Latin America Urological Cancer Therapeutics Drugs Sales by Country
3.6.2 Latin America Urological Cancer Therapeutics Drugs Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country
3.7.2 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Urological Cancer Therapeutics Drugs Historic Market Analysis by Type
4.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
4.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2015-2020)
4.3 Global Urological Cancer Therapeutics Drugs Price Market Share by Type (2015-2020)
4.4 Global Urological Cancer Therapeutics Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Global Urological Cancer Therapeutics Drugs Historic Market Analysis by Application
5.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
5.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2015-2020)
5.3 Global Urological Cancer Therapeutics Drugs Price by Application (2015-2020)
6 Company Profiles and Key Figures in Urological Cancer Therapeutics Drugs Business
6.1 Novartis
6.1.1 Corporation Information
6.1.2 Novartis Description, Business Overview and Total Revenue
6.1.3 Novartis Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Novartis Products Offered
6.1.5 Novartis Recent Development
6.2 Pfizer
6.2.1 Pfizer Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.2.2 Pfizer Description, Business Overview and Total Revenue
6.2.3 Pfizer Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Pfizer Products Offered
6.2.5 Pfizer Recent Development
6.3 Johnson & Johnson
6.3.1 Johnson & Johnson Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.3.2 Johnson & Johnson Description, Business Overview and Total Revenue
6.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Johnson & Johnson Products Offered
6.3.5 Johnson & Johnson Recent Development
6.4 AstraZeneca
6.4.1 AstraZeneca Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.4.2 AstraZeneca Description, Business Overview and Total Revenue
6.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.4.4 AstraZeneca Products Offered
6.4.5 AstraZeneca Recent Development
6.5 Astellas
6.5.1 Astellas Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.5.2 Astellas Description, Business Overview and Total Revenue
6.5.3 Astellas Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Astellas Products Offered
6.5.5 Astellas Recent Development
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.6.2 Bristol-Myers Squibb Description, Business Overview and Total Revenue
6.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.6.4 Bristol-Myers Squibb Products Offered
6.6.5 Bristol-Myers Squibb Recent Development
6.7 Abbott Laboratories
6.6.1 Abbott Laboratories Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.6.2 Abbott Laboratories Description, Business Overview and Total Revenue
6.6.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Abbott Laboratories Products Offered
6.7.5 Abbott Laboratories Recent Development
6.8 Celgene Corporation
6.8.1 Celgene Corporation Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.8.2 Celgene Corporation Description, Business Overview and Total Revenue
6.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.8.4 Celgene Corporation Products Offered
6.8.5 Celgene Corporation Recent Development
6.9 Dendreon Corporation
6.9.1 Dendreon Corporation Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.9.2 Dendreon Corporation Description, Business Overview and Total Revenue
6.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Dendreon Corporation Products Offered
6.9.5 Dendreon Corporation Recent Development
6.10 Ferring Pharmaceuticals
6.10.1 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.10.2 Ferring Pharmaceuticals Description, Business Overview and Total Revenue
6.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.10.4 Ferring Pharmaceuticals Products Offered
6.10.5 Ferring Pharmaceuticals Recent Development
6.11 GlaxoSmithKline plc
6.11.1 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.11.2 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Description, Business Overview and Total Revenue
6.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.11.4 GlaxoSmithKline plc Products Offered
6.11.5 GlaxoSmithKline plc Recent Development
6.12 Indevus Pharmaceuticals Inc
6.12.1 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.12.2 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Description, Business Overview and Total Revenue
6.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.12.4 Indevus Pharmaceuticals Inc Products Offered
6.12.5 Indevus Pharmaceuticals Inc Recent Development
6.13 Ipsen
6.13.1 Ipsen Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.13.2 Ipsen Urological Cancer Therapeutics Drugs Description, Business Overview and Total Revenue
6.13.3 Ipsen Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.13.4 Ipsen Products Offered
6.13.5 Ipsen Recent Development
6.14 Roche Healthcare
6.14.1 Roche Healthcare Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.14.2 Roche Healthcare Urological Cancer Therapeutics Drugs Description, Business Overview and Total Revenue
6.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.14.4 Roche Healthcare Products Offered
6.14.5 Roche Healthcare Recent Development
6.15 Sanofi S.A.
6.15.1 Sanofi S.A. Urological Cancer Therapeutics Drugs Production Sites and Area Served
6.15.2 Sanofi S.A. Urological Cancer Therapeutics Drugs Description, Business Overview and Total Revenue
6.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
6.15.4 Sanofi S.A. Products Offered
6.15.5 Sanofi S.A. Recent Development
7 Urological Cancer Therapeutics Drugs Manufacturing Cost Analysis
7.1 Urological Cancer Therapeutics Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs
7.4 Urological Cancer Therapeutics Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Urological Cancer Therapeutics Drugs Distributors List
8.3 Urological Cancer Therapeutics Drugs Customers
9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis
10 Global Market Forecast
10.1 Global Urological Cancer Therapeutics Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Urological Cancer Therapeutics Drugs by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Urological Cancer Therapeutics Drugs by Type (2021-2026)
10.2 Urological Cancer Therapeutics Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Urological Cancer Therapeutics Drugs by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Urological Cancer Therapeutics Drugs by Application (2021-2026)
10.3 Urological Cancer Therapeutics Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Urological Cancer Therapeutics Drugs by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Urological Cancer Therapeutics Drugs by Region (2021-2026)
10.4 North America Urological Cancer Therapeutics Drugs Estimates and Projections (2021-2026)
10.5 Europe Urological Cancer Therapeutics Drugs Estimates and Projections (2021-2026)
10.6 Asia Pacific Urological Cancer Therapeutics Drugs Estimates and Projections (2021-2026)
10.7 Latin America Urological Cancer Therapeutics Drugs Estimates and Projections (2021-2026)
10.8 Middle East and Africa Urological Cancer Therapeutics Drugs Estimates and Projections (2021-2026)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
Read More
List of Tables
    Table 1. Global Urological Cancer Therapeutics Drugs Sales (K MT) Growth Rate Comparison by Type (2015-2026)
    Table 2. Global Urological Cancer Therapeutics Drugs Sales (K MT) Comparison by Application: 2020 VS 2026
    Table 3. Global Urological Cancer Therapeutics Drugs Market Size by Type (K MT) (US$ Million) (2020 VS 2026)
    Table 4. Global Key Urological Cancer Therapeutics Drugs Manufacturers Covered in This Study
    Table 5. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Manufacturers (2015-2020)
    Table 6. Global Urological Cancer Therapeutics Drugs Sales Share by Manufacturers (2015-2020)
    Table 7. Global Urological Cancer Therapeutics Drugs Revenue (Million USD) by Manufacturers (2015-2020)
    Table 8. Global Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2015-2020)
    Table 9. Global Market Urological Cancer Therapeutics Drugs Average Price (USD/MT) of Key Manufacturers (2015-2020)
    Table 10. Manufacturers Urological Cancer Therapeutics Drugs Sales Sites and Area Served
    Table 11. Manufacturers Urological Cancer Therapeutics Drugs Product Types
    Table 12. Global Urological Cancer Therapeutics Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Urological Cancer Therapeutics Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2019)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Main Points Interviewed from Key Urological Cancer Therapeutics Drugs Players
    Table 16. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Region (2015-2020)
    Table 17. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region (2015-2020)
    Table 18. Global Urological Cancer Therapeutics Drugs Revenue (Million US$) by Region (2015-2020)
    Table 19. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2015-2020)
    Table 20. North America Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)
    Table 21. North America Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)
    Table 22. North America Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 23. North America Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)
    Table 24. Europe Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)
    Table 25. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)
    Table 26. Europe Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 27. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)
    Table 28. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region (2015-2020) (K MT)
    Table 29. Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Region (2015-2020)
    Table 30. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region (2015-2020) (US$ Million)
    Table 31. Asia Pacific Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2015-2020)
    Table 32. Latin America Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)
    Table 33. Latin America Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)
    Table 34. Latin America Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 35. Latin America Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)
    Table 36. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)
    Table 37. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)
    Table 38. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 39. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)
    Table 40. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2015-2020)
    Table 41. Global Urological Cancer Therapeutics Drugs Sales Share by Type (2015-2020)
    Table 42. Global Urological Cancer Therapeutics Drugs Revenue (Million US$) by Type (2015-2020)
    Table 43. Global Urological Cancer Therapeutics Drugs Revenue Share by Type (2015-2020)
    Table 44. Global Urological Cancer Therapeutics Drugs Price (USD/MT) by Type (2015-2020)
    Table 45. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Application (2015-2020)
    Table 46. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
    Table 47. Global Urological Cancer Therapeutics Drugs Sales Growth Rate by Application (2015-2020)
    Table 48. Novartis Urological Cancer Therapeutics Drugs Corporation Information
    Table 49. Novartis Description and Business Overview
    Table 50. Novartis Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 51. Novartis Main Product
    Table 52. Novartis Recent Development
    Table 53. Pfizer Urological Cancer Therapeutics Drugs Corporation Information
    Table 54. Pfizer Corporation Information
    Table 55. Pfizer Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 56. Pfizer Main Product
    Table 57. Pfizer Recent Development
    Table 58. Johnson & Johnson Urological Cancer Therapeutics Drugs Corporation Information
    Table 59. Johnson & Johnson Corporation Information
    Table 60. Johnson & Johnson Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 61. Johnson & Johnson Main Product
    Table 62. Johnson & Johnson Recent Development
    Table 63. AstraZeneca Urological Cancer Therapeutics Drugs Corporation Information
    Table 64. AstraZeneca Corporation Information
    Table 65. AstraZeneca Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 66. AstraZeneca Main Product
    Table 67. AstraZeneca Recent Development
    Table 68. Astellas Urological Cancer Therapeutics Drugs Corporation Information
    Table 69. Astellas Corporation Information
    Table 70. Astellas Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 71. Astellas Main Product
    Table 72. Astellas Recent Development
    Table 73. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Corporation Information
    Table 74. Bristol-Myers Squibb Corporation Information
    Table 75. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 76. Bristol-Myers Squibb Main Product
    Table 77. Bristol-Myers Squibb Recent Development
    Table 78. Abbott Laboratories Urological Cancer Therapeutics Drugs Corporation Information
    Table 79. Abbott Laboratories Corporation Information
    Table 80. Abbott Laboratories Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 81. Abbott Laboratories Main Product
    Table 82. Abbott Laboratories Recent Development
    Table 83. Celgene Corporation Urological Cancer Therapeutics Drugs Corporation Information
    Table 84. Celgene Corporation Corporation Information
    Table 85. Celgene Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 86. Celgene Corporation Main Product
    Table 87. Celgene Corporation Recent Development
    Table 88. Dendreon Corporation Urological Cancer Therapeutics Drugs Corporation Information
    Table 89. Dendreon Corporation Corporation Information
    Table 90. Dendreon Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 91. Dendreon Corporation Main Product
    Table 92. Dendreon Corporation Recent Development
    Table 93. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Corporation Information
    Table 94. Ferring Pharmaceuticals Corporation Information
    Table 95. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 96. Ferring Pharmaceuticals Main Product
    Table 97. Ferring Pharmaceuticals Recent Development
    Table 98. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Corporation Information
    Table 99. GlaxoSmithKline plc Corporation Information
    Table 100. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 101. GlaxoSmithKline plc Main Product
    Table 102. GlaxoSmithKline plc Recent Development
    Table 103. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Corporation Information
    Table 104. Indevus Pharmaceuticals Inc Corporation Information
    Table 105. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 106. Indevus Pharmaceuticals Inc Main Product
    Table 107. Indevus Pharmaceuticals Inc Recent Development
    Table 108. Ipsen Urological Cancer Therapeutics Drugs Corporation Information
    Table 109. Ipsen Corporation Information
    Table 110. Ipsen Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 111. Ipsen Main Product
    Table 112. Ipsen Recent Development
    Table 113. Roche Healthcare Urological Cancer Therapeutics Drugs Corporation Information
    Table 114. Roche Healthcare Corporation Information
    Table 115. Roche Healthcare Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 116. Roche Healthcare Main Product
    Table 117. Roche Healthcare Recent Development
    Table 118. Sanofi S.A. Urological Cancer Therapeutics Drugs Corporation Information
    Table 119. Sanofi S.A. Corporation Information
    Table 120. Sanofi S.A. Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 121. Sanofi S.A. Main Product
    Table 122. Sanofi S.A. Recent Development
    Table 123. Sales Base and Market Concentration Rate of Raw Material
    Table 124. Key Suppliers of Raw Materials
    Table 125. Urological Cancer Therapeutics Drugs Distributors List
    Table 126. Urological Cancer Therapeutics Drugs Customers List
    Table 127. Market Key Trends
    Table 128. Key Opportunities and Drivers: Impact Analysis (2021-2026)
    Table 129. Key Challenges
    Table 130. Global Urological Cancer Therapeutics Drugs Sales (K MT) Forecast by Type (2021-2026)
    Table 131. Global Urological Cancer Therapeutics Drugs Sales Market Share Forecast by Type (2021-2026)
    Table 132. Global Urological Cancer Therapeutics Drugs Revenue (Million US$) Forecast by Type (2021-2026)
    Table 133. Global Urological Cancer Therapeutics Drugs Revenue (Million US$) Market Share Forecast by Type (2021-2026)
    Table 134. Global Urological Cancer Therapeutics Drugs Sales (K MT) Forecast by Application (2021-2026)
    Table 135. Global Urological Cancer Therapeutics Drugs Revenue (Million US$) Forecast by Application (2021-2026)
    Table 136. Global Urological Cancer Therapeutics Drugs Sales (K MT) Forecast by Region (2021-2026)
    Table 137. Global Urological Cancer Therapeutics Drugs Sales Market Share Forecast by Region (2021-2026)
    Table 138. Global Urological Cancer Therapeutics Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
    Table 139. Global Urological Cancer Therapeutics Drugs Revenue Market Share Forecast by Region (2021-2026)
    Table 140. Research Programs/Design for This Report
    Table 141. Key Data Information from Secondary Sources
    Table 142. Key Data Information from Primary Sources
List of Figures
    Figure 1. Picture of Urological Cancer Therapeutics Drugs
    Figure 2. Global Urological Cancer Therapeutics Drugs Sales Market Share by Type: 2020 VS 2026
    Figure 3. Xofigo (radium Ra 223 dichloride) Product Picture
    Figure 4. Jevtana (cabazitaxel) Product Picture
    Figure 5. Inlyta (axitinib) Product Picture
    Figure 6. Votrient (pazopanib hydrochloride) Product Picture
    Figure 7. Sutent (sunitinib malate) Product Picture
    Figure 8. Zytiga (abiraterone acetate) Product Picture
    Figure 9. Xtandi (enzalutamide) Product Picture
    Figure 10. Opdivo (nivolumab) Product Picture
    Figure 11. Provenge (sipuleucel-T) Product Picture
    Figure 12. Global Urological Cancer Therapeutics Drugs Consumption Market Share by Application: 2020 VS 2026
    Figure 13. Hospital
    Figure 14. Medical Research Laboratory
    Figure 15. Others
    Figure 16. Global Urological Cancer Therapeutics Drugs Market Size 2015-2026 (US$ Million)
    Figure 17. Global Urological Cancer Therapeutics Drugs Sales Capacity (K MT) (2015-2026)
    Figure 18. Global Urological Cancer Therapeutics Drugs Market Size Market Share by Region: 2020 Versus 2026
    Figure 19. Urological Cancer Therapeutics Drugs Sales Share by Manufacturers in 2020
    Figure 20. Global Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers in 2019
    Figure 21. The Global 5 and 10 Largest Players: Market Share by Urological Cancer Therapeutics Drugs Revenue in 2019
    Figure 22. Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
    Figure 23. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region (2015-2020)
    Figure 24. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region in 2019
    Figure 25. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2015-2020)
    Figure 26. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region in 2019
    Figure 27. North America Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019
    Figure 28. North America Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019
    Figure 29. U.S. Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 30. U.S. Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 31. Canada Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 32. Canada Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 33. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019
    Figure 34. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019
    Figure 35. Germany Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 36. Germany Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 37. France Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 38. France Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 39. U.K. Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 40. U.K. Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 41. Italy Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 42. Italy Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 43. Russia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 44. Russia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 45. Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Region in 2019
    Figure 46. Asia Pacific Urological Cancer Therapeutics Drugs Revenue Market Share by Region in 2019
    Figure 47. China Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 48. China Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 49. Japan Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 50. Japan Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 51. South Korea Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 52. South Korea Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 53. India Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 54. India Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 55. Australia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 56. Australia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 57. Taiwan Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 58. Taiwan Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 59. Indonesia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 60. Indonesia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 61. Thailand Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 62. Thailand Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 63. Malaysia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 64. Malaysia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 65. Philippines Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 66. Philippines Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 67. Vietnam Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 68. Vietnam Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 69. Latin America Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019
    Figure 70. Latin America Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019
    Figure 71. Mexico Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 72. Mexico Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 73. Brazil Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 74. Brazil Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 75. Argentina Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 76. Argentina Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 77. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019
    Figure 78. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019
    Figure 79. Turkey Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 80. Turkey Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 81. Saudi Arabia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 82. Saudi Arabia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 83. U.A.E Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 84. U.A.E Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 85. Sales Market Share of Urological Cancer Therapeutics Drugs by Type (2015-2020)
    Figure 86. Sales Market Share of Urological Cancer Therapeutics Drugs by Type in 2019
    Figure 87. Revenue Share of Urological Cancer Therapeutics Drugs by Type (2015-2020)
    Figure 88. Revenue Market Share of Urological Cancer Therapeutics Drugs by Type in 2019
    Figure 89. Global Urological Cancer Therapeutics Drugs Sales Growth by Type (2015-2020) (K MT)
    Figure 90. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
    Figure 91. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application in 2019
    Figure 92. Global Revenue Share of Urological Cancer Therapeutics Drugs by Application (2015-2020)
    Figure 93. Global Revenue Share of Urological Cancer Therapeutics Drugs by Application in 2020
    Figure 94. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 95. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 96. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 97. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 98. Astellas Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 99. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 100. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 101. Celgene Corporation Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 102. Dendreon Corporation Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 103. Ferring Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 104. GlaxoSmithKline plc Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 105. Indevus Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 106. Ipsen Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 107. Roche Healthcare Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 108. Sanofi S.A. Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 109. Price Trend of Key Raw Materials
    Figure 110. Manufacturing Cost Structure of Urological Cancer Therapeutics Drugs
    Figure 111. Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs
    Figure 112. Urological Cancer Therapeutics Drugs Industrial Chain Analysis
    Figure 113. Channels of Distribution
    Figure 114. Distributors Profiles
    Figure 115. Porter's Five Forces Analysis
    Figure 116. North America Urological Cancer Therapeutics Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 117. North America Urological Cancer Therapeutics Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 118. Europe Urological Cancer Therapeutics Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 119. Europe Urological Cancer Therapeutics Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 120. Latin America Urological Cancer Therapeutics Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 121. Latin America Urological Cancer Therapeutics Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 122. Middle East and Africa Urological Cancer Therapeutics Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 123. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 124. Asia Pacific Urological Cancer Therapeutics Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 125. Asia Pacific Urological Cancer Therapeutics Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 126. Bottom-up and Top-down Approaches for This Report
    Figure 127. Data Triangulation
    Figure 128. Key Executives Interviewed
Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$2900
This license allows only one user(purchaser of the report) to access the PDF.

Multi User

Electronic (PDF)
$4350
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)
$5800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Leap India

RELATED REPORTS

Global Bio identical Hormones Replacement Therapy Market Size Status and Forecast 2021 2027
Global Bio-identical Hormones Replacement Therapy Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-12D4239
Wed Jan 27 00:00:00 UTC 2021

Add to Cart

Global Testosterone Replacement Therapy Market Research Report 2021
Global Testosterone Replacement Therapy Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-19S4161
Wed Jan 27 00:00:00 UTC 2021

Add to Cart

Global Erectile Dysfunction Devices Market Research Report 2021
Global Erectile Dysfunction Devices Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-5P4318
Wed Jan 27 00:00:00 UTC 2021

Add to Cart

Global Erection Ring Market Research Report 2021
Global Erection Ring Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-35Y4047
Wed Jan 27 00:00:00 UTC 2021

Add to Cart

0 Items
X
No items in the cart.
$0.0